Publications in collaboration with researchers from Centro de Investigación Médica Aplicada (2)

2017

  1. Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair

    Journal of Hematology and Oncology, Vol. 10, Núm. 1

  2. The novel pan-PIM kinase inhibitor, PIM447, displays dual antimyeloma and bone-protective effects, and potently synergizes with current standards of care

    Clinical Cancer Research, Vol. 23, Núm. 1, pp. 225-238